KRAS Wild-Type Lung Cancer: A Moving Target in an Era of Genotype Migration
Author:
Affiliation:
1. Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2012.43.2740
Reference27 articles.
1. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
3. Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS)
4. First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
5. The “Lazarus Response” in Treatment-Naïve, Poor Performance Status Patients With Non–Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. KRASoncogene in lung cancer: focus on molecularly driven clinical trials;European Respiratory Review;2016-02-29
2. Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis;Journal of Cancer Research and Clinical Oncology;2015-01-11
3. Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer;Expert Opinion on Investigational Drugs;2014-06-12
4. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer;European Journal of Cancer;2014-06
5. The clinical relevance of KRAS gene mutation in non-small-cell lung cancer;Current Opinion in Oncology;2014-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3